Teva Pharmaceuticals Competitors and Similar CompaniesClear all
Teva Pharmaceuticals's competitors and similar companies include Viatris, Novartis and Pfizer.
 Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | ||
Founding Date | Founding Date 1901 | Founding Date 2020 | Founding Date 1996 | Founding Date 1849 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Petah Tikva, IL HQ Villa Adelina, AR Macquarie Park, AU Minsk, BY Antwerpen, BE Sao Paulo, BR Dupnica, BG see more | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more |
Employees | Employees 37,000 | Employees 38,0003% increase | Employees 75,883 | Employees 81,0008% decrease |
Valuation ($) | Valuation ($) 20.8 b | Valuation ($) 14 b | Valuation ($) N/A | Valuation ($) 163.9 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $17.3b (FY, 2025) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) |
Cost of goods | Cost of goods $8.3b (FY, 2025) | Cost of goods $9.3b (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.1b (FY, 2025) |
Gross profit | Gross profit $8.9b (FY, 2025) | Gross profit $5b (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit $46.5b (FY, 2025) |
Net income | Net income $1.4b (FY, 2025) | Net income ($3.5b) (FY, 2025) | Net income $14b (FY, 2025) | Net income $7.8b (FY, 2025) |
Operating ⚠ | ||||
Countries | Countries N/A | Countries 165 (Q1, 2023) | Countries N/A | Countries 200 (FY, 2024) |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites 40 (Q1, 2023) | Manufacturing Sites N/A | Manufacturing Sites 37 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2024) |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 5 (FY, 2024) |
Funding | ||||
Total funding raised | Total funding raised $ 358m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Viatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View company